Patents by Inventor Joseph William Epstein

Joseph William Epstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
    Patent number: 7098230
    Abstract: The present invention relates to (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: August 29, 2006
    Assignee: DOV Pharmaceutical, Inc.
    Inventors: Arnold Stan Lippa, Joseph William Epstein
  • (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
    Patent number: 7081471
    Abstract: The present invention relates to (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: July 25, 2006
    Assignee: DOV Pharmaceutical, Inc.
    Inventors: Arnold Stan Lippa, Joseph William Epstein
  • (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
    Patent number: 7041835
    Abstract: The present invention relates to (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: May 9, 2006
    Assignee: Dor Pharmaceutical, Inc.
    Inventors: Arnold Stan Lippa, Joseph William Epstein
  • 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6949661
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: September 27, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6861445
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: March 1, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6784184
    Abstract: This invention relates to a method of using novel 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones of Formula (I), wherein Ar, Ar′, R6, m and n are as defined in the specification as inhibitors of Ras FPTase, and may be used as an alternative to, or in conjunction with, traditional cancer therapy for treating ras-oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: August 31, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian, Gary Harold Birnberg, Edward James Salaski, Gloria Jean Macewan, Katherine Cheung
  • (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
    Publication number: 20040157869
    Abstract: The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
    Type: Application
    Filed: January 23, 2004
    Publication date: August 12, 2004
    Applicant: DOV Pharmaceutical, Inc.
    Inventors: Arnold Stan Lippa, Joseph William Epstein
  • (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
    Publication number: 20040157908
    Abstract: The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
    Type: Application
    Filed: January 23, 2004
    Publication date: August 12, 2004
    Applicant: DOV Pharmaceutical, Inc.
    Inventors: Arnold Stan Lippa, Joseph William Epstein
  • (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
    Publication number: 20040157870
    Abstract: The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
    Type: Application
    Filed: January 23, 2004
    Publication date: August 12, 2004
    Inventors: Arnold Stan Lippa, Joseph William Epstein
  • 3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6740675
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: May 25, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • 5-(Substituted)-5-(substitutedsulfonyl or sulfanyl) thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6716862
    Abstract: The invention relates to compounds of Formula (I) wherein R1, (R2)v, R3 and n are defined in the specification and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: April 6, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Edward James Salaski, Semiramis Ayral-Kaloustian, Joseph William Epstein
  • (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
    Patent number: 6716868
    Abstract: The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
    Type: Grant
    Filed: April 29, 2003
    Date of Patent: April 6, 2004
    Assignee: DOV Pharmaceutical Inc
    Inventors: Arnold Stan Lippa, Joseph William Epstein
  • 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Publication number: 20040063971
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Application
    Filed: September 26, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Publication number: 20040063777
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Application
    Filed: September 26, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • (-)-1-(3,4-DichlorophenyI)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
    Publication number: 20030181508
    Abstract: The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
    Type: Application
    Filed: April 29, 2003
    Publication date: September 25, 2003
    Applicant: Dov Pharmaceuticals, Inc.
    Inventors: Arnold Stan Lippa, Joseph William Epstein
  • Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
    Patent number: 6605628
    Abstract: This invention relates to a method of using novel 5-(arylsulfonyl)-5-(arylsulfinyl)- and 5-(arylsulfanyl)thiazolidine-2,4-diones of Formula (I), wherein Ar, Ar′, R6, m and n are as defined in the specification as inhibitors of Ras FPTase, and may be used as an alternative to, or in conjunction with, traditional cancer therapy for treating ras- oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: August 12, 2003
    Assignee: Wyeth Holdings Corporation
    Inventors: Semiramis Ayral-Kaloustian, Joseph William Epstein, Gary H. Birnberg, Edward James Salaski, Gloria Jean Macewan, Katherine Cheung
  • 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
    Publication number: 20030149063
    Abstract: This invention relates to a method of using novel 5-(arylsulfonyl)-,5- (arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones of Formula (I), wherein Ar, Ar′, R6, m and n are as defined in the specification as inhibitors of Ras FPTase, and may be used as an alternative to, or in conjunction with, traditional cancer therapy for treating ras- oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Application
    Filed: August 23, 2002
    Publication date: August 7, 2003
    Applicant: American Cyanamid Company
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian, Gary Harold Birnberg, Edward James Salaski, Gloria Jean Macewan, Katherine Cheung
  • Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
    Publication number: 20030144301
    Abstract: This invention relates to a method of using novel 5-(arylsulfonyl)-, 5-(arylsulfinyl)- and 5-(arylsulfanyl)thiazolidine-2,4-diones of Formula (1), wherein Ar, Ar′, R6, m and n are as defined in the specification as inhibitors of Ras FPTase, and may be used as an alternative to, or in conjunction with, traditional cancer therapy for treating ras- oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Application
    Filed: August 23, 2002
    Publication date: July 31, 2003
    Applicant: American Cyanamid Company
    Inventors: Semiramis Ayral-Kaloustian, Joseph William Epstein, Gary H. Birnberg, Edward James Salaski, Gloria Macewan, Katherine Cheung
  • (?)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
    Patent number: 6569887
    Abstract: The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: May 27, 2003
    Assignee: Dov Pharmaceuticals Inc.
    Inventors: Arnold Stan Lippa, Joseph William Epstein
  • 5-(Substituted)-5-(substitutedsulfonyl or sulfanyl) thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
    Publication number: 20030096849
    Abstract: The invention relates to compounds of Formula (I) wherein R1, (R2)v, R3 and n are defined in the specification and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Application
    Filed: August 23, 2002
    Publication date: May 22, 2003
    Applicant: American Cyanamid Company
    Inventors: Edward James Salaski, Semiramis Ayral-Kaloustian, Joseph William Epstein